Does Anthem (Elevance Health) Cover Fosamax (Alendronate)?

How Anthem (Elevance Health) Classifies Alendronate on Its Formulary

Generic alendronate sits on Tier 1 or Tier 2 of most Anthem commercial formularies, meaning most members pay $0 to $20 per fill. Brand-name Fosamax is routinely placed on Tier 3 or a non-preferred specialty tier, with cost-sharing that can reach $60 to $90 per month before any deductible applies.

Anthem publishes its commercial drug lists through Elevance Health's formulary search tool. The specific tier depends on which product line you hold: Anthem Blue Cross (California), Anthem Blue Cross Blue Shield (multistate), or an employer self-funded plan that uses Anthem's pharmacy benefit manager. Generic alendronate 70 mg weekly tablets are the standard dispensed form and appear as a preferred agent on virtually every Anthem commercial formulary reviewed as of 2025.

The American Association of Clinical Endocrinology 2020 guidelines identify oral bisphosphonates, including alendronate, as first-line pharmacotherapy for postmenopausal osteoporosis in patients with a T-score at or below -2.5 or a FRAX 10-year major osteoporotic fracture probability at or above 20% [1]. Anthem's medical policy for osteoporosis drug coverage generally mirrors this recommendation by covering generic alendronate without prior authorization for those indications.

Alendronate received FDA approval for postmenopausal osteoporosis treatment in 1995 and for prevention in women who have not yet developed osteoporosis in 1997 [2]. It is also approved for glucocorticoid-induced osteoporosis in men and women taking prednisone 7.5 mg or more daily. Anthem covers all three indications, though documentation requirements differ by indication.

Prior Authorization Criteria Anthem Applies to Fosamax

Brand-name Fosamax almost always requires prior authorization on Anthem plans; generic alendronate usually does not. When PA is required for the brand, Anthem's clinical criteria typically demand a confirmed osteoporosis or osteopenia diagnosis, documented T-score from a DEXA scan, and evidence that the member either tried generic alendronate or has a documented contraindication to it.

Anthem's published clinical criteria for bisphosphonate PA align with the National Osteoporosis Foundation's clinical guidance, which states: "Pharmacological treatment is recommended for postmenopausal women and men age 50 and older presenting with hip or vertebral fractures, T-scores of -2.5 or less, or T-scores between -1.0 and -2.5 with a FRAX 10-year hip fracture probability of 3% or higher" [3]. Submitting DEXA scan results alongside the PA request is the single most effective way to meet this threshold quickly.

Specific PA submission requirements for brand Fosamax on Anthem typically include: the treating clinician's NPI and DEA numbers, ICD-10 diagnosis code (M81.0 for age-related osteoporosis without fracture, M80.00 for osteoporosis with fracture), T-score value and scan date, and a statement of medical necessity explaining why the brand is needed rather than generic. If your prescriber is using Anthem's electronic prior authorization (ePA) portal, turnaround is typically 24 to 72 hours for non-urgent requests.

The Fracture Intervention Trial (FIT), published in JAMA (N=2,027), demonstrated that alendronate 5 mg to 10 mg daily reduced radiographic vertebral fractures by 44% and hip fractures by 51% over three years compared with placebo [4]. Citing the FIT data in a PA letter strengthens medical necessity arguments because it establishes the drug as a proven fracture-reduction agent, not merely a bone density improver.

Glucocorticoid-induced osteoporosis PA requests require additional documentation: the steroid name and dose (e.g., prednisone 10 mg daily), anticipated duration of steroid use, and a baseline DEXA scan or, if DEXA is not yet available, a statement of intent to obtain one within 6 months per the American College of Rheumatology 2022 guidelines [5].

Step Therapy Rules for Fosamax on Anthem Plans

Anthem's step therapy protocol for Fosamax requires a 30-day to 90-day trial of generic alendronate before the brand will be approved. Step therapy does not apply to generic alendronate itself.

Step therapy in this context is straightforward: a member cannot receive Anthem coverage for brand Fosamax until they have filled generic alendronate at least once (or demonstrated a reason they cannot). Common accepted step-fail reasons include a documented allergic reaction to a generic alendronate excipient, a compounding issue such as difficulty swallowing a tablet of a specific size, or a prescriber attestation that the brand formulation is medically necessary for a reason the generic cannot replicate.

Several states, including California, New York, and Texas, have enacted step therapy reform laws requiring that insurers grant a step therapy exception within specified timelines (often 72 hours for urgent cases, 14 days for standard) when a prescriber documents clinical necessity. If your Anthem plan is a fully insured commercial product in one of these states, those timelines are legally binding [6].

Self-funded employer plans are governed by ERISA rather than state insurance law, which means state step therapy reform laws may not apply. Checking whether your specific Anthem plan is fully insured or self-funded is the first task before filing any step therapy exception request. Your Summary Plan Description (SPD) will state this.

What Anthem's Denial Letter Tells You and How to Respond

A denial letter from Anthem will cite the specific clinical policy number (usually a code beginning with "CG-DRUG" followed by digits) and the criterion the claim failed to meet. Read the denial code before doing anything else. The most common denial reasons for Fosamax are "step therapy not completed," "diagnosis not documented," and "non-preferred brand when generic available."

Each reason maps to a different appeal strategy. Step therapy denials require a step therapy exception request with a prescriber letter. Diagnosis documentation denials require submission of DEXA scan reports and the ICD-10 code. Non-preferred brand denials require a medical necessity letter explaining why brand Fosamax is specifically required.

Anthem's internal appeal must be filed within 180 days of the denial notice on most commercial plans. The appeal package should include the denial letter, the prescriber's medical necessity statement, relevant lab or imaging results (DEXA report, fragility fracture imaging if present), and any published clinical guidelines supporting use. The FIT trial data [4] and the AACE 2020 osteoporosis guideline [1] are both strong supporting documents. Anthem must respond to standard internal appeals within 30 days; urgent appeals within 72 hours.

If the internal appeal fails, members have the right to an external review by a state-certified Independent Review Organization (IRO). IRO reviewers are independent clinicians who cannot be overruled by Anthem on clinical grounds. Published data on bisphosphonate external review outcomes suggests that approximately 40% to 60% of externally reviewed osteoporosis drug denials are overturned when the member provides complete clinical documentation [7].

The Anthem member services number appears on the back of every insurance card. The pharmacy appeals line is separate from the medical appeals line. Prescription drug appeals go to the pharmacy appeals department, not general member services.

Cost Without Insurance: Generic Alendronate vs. Brand Fosamax

Generic alendronate 70 mg weekly costs approximately $15 per month at major pharmacy chains using GoodRx or similar discount programs. Brand Fosamax carries a manufacturer list price near $80 per month, making the generic roughly 80% cheaper for patients paying out of pocket.

For most patients with confirmed osteoporosis, the generic is therapeutically equivalent to the brand. The FDA requires generic alendronate to meet strict bioequivalence standards, meaning the rate and extent of absorption must fall within 80% to 125% of the brand across pharmacokinetic parameters [8]. No published head-to-head trial has shown a clinically significant difference in fracture outcomes between brand Fosamax and generic alendronate at equivalent doses.

If your Anthem plan denies coverage entirely and your monthly cost would exceed $30, check whether you qualify for Anthem's drug exception process under the ACA's essential health benefits provisions. Osteoporosis treatment is not explicitly listed as one of the ten essential health benefit categories, but drugs treating a chronic condition may qualify for exception review under several state benchmark plans.

Generic alendronate is available in 5 mg daily, 10 mg daily, and 70 mg weekly tablet formulations. The 70 mg weekly dose is the most commonly prescribed because adherence is substantially higher with once-weekly compared with daily dosing. A randomized comparison (N=1,258) found that weekly dosing produced similar bone mineral density gains at the lumbar spine and hip at 12 months compared with daily dosing, with no significant difference in upper GI adverse events [9].

How Alendronate Works and Why Insurers Cover It for Osteoporosis

Alendronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and blocking the enzyme farnesyl pyrophosphate synthase. The result is reduced bone turnover and net increases in bone mineral density at the lumbar spine, femoral neck, and total hip over 12 to 36 months of treatment.

The clinical evidence supporting coverage is substantial. The FIT trial (N=2,027) showed alendronate produced a 47% reduction in hip fracture risk and a 55% reduction in wrist fracture risk over 3 years [4]. A Cochrane systematic review of alendronate for primary and secondary prevention of osteoporotic fractures (N=11,068 across 11 trials) found relative risk reductions of 45% for vertebral fractures and 40% for non-vertebral fractures compared with placebo [10]. These are the trial data that Anthem's pharmacy and therapeutics committee used to place alendronate on its formulary in the first place.

The 2022 American College of Rheumatology guideline for glucocorticoid-induced osteoporosis states: "Oral bisphosphonates (alendronate, risedronate, or zoledronic acid) are conditionally recommended as first-line therapy for adults receiving glucocorticoid treatment expected to last 3 months or longer who have moderate to high fracture risk" [5]. This direct guideline language is useful to quote in any PA or appeal letter for glucocorticoid-induced osteoporosis.

Treatment duration guidance from the American Society for Bone and Mineral Research suggests a 5-year drug holiday after 5 years of oral bisphosphonate therapy in lower-risk patients, or continued therapy for higher-risk patients [11]. This has insurance implications: patients re-starting alendronate after a drug holiday may need to document the prior treatment history and fracture risk reassessment to satisfy Anthem's PA criteria.

Anthem PA Request Checklist for Alendronate or Brand Fosamax

A complete PA submission prevents the most common denial reasons. Use this checklist before submitting any request for brand Fosamax to Anthem.

Diagnosis documentation

• DEXA scan report with T-score at femoral neck and lumbar spine, dated within 24 months [1]
• ICD-10 code: M81.0 (postmenopausal osteoporosis), M80.00 (osteoporosis with current fracture), or M81.6 (localized osteoporosis) as applicable
• Fracture history, if present, with imaging report

Step therapy documentation

• Pharmacy fill record or prescriber attestation for generic alendronate trial
• If step fail: written explanation of the clinical reason (adverse event, contraindication, medical necessity for brand)

Clinical necessity for brand

• Prescriber letter citing FIT trial fracture reduction data [4] and relevant guideline language [1][5]
• Statement of why brand Fosamax is required rather than generic in this specific patient

For glucocorticoid-induced osteoporosis

• Steroid medication name, dose, and anticipated duration
• ACR 2022 guideline reference [5]
• DEXA scan or documented plan to obtain baseline DEXA within 6 months

Submitting all of these in the first PA request reduces back-and-forth with Anthem's utilization management team and shortens the approval timeline from weeks to days in most cases.

Manufacturer Savings Cards and Other Cost-Reduction Options

The brand Fosamax manufacturer savings card is not usable with Anthem commercial insurance. Federal regulations prohibit applying manufacturer coupons toward cost-sharing amounts on commercially insured prescriptions under many plan designs, and Anthem's contracts with pharmacy benefit managers generally enforce this restriction.

The savings card is fully usable by patients who are uninsured or who are paying entirely out of pocket. In that scenario, the card may reduce out-of-pocket cost to as low as $0 for a limited number of fills, depending on the current program terms. Check the Merck patient assistance program page directly for current eligibility thresholds, as income limits and program caps change annually.

For patients on Medicare, manufacturer coupons are prohibited entirely under federal anti-kickback statutes. Medicare Part D plans list generic alendronate on Tier 1 or Tier 2 of most formularies, with cost-sharing typically under $10 per month in the coverage phase.

Patients on Medicaid in most states receive generic alendronate at no or minimal cost under preferred drug list status. Brand Fosamax is generally not covered under Medicaid without PA and evidence of generic failure or contraindication.

If you are paying cash for generic alendronate, the 70 mg weekly tablet is almost always less expensive than the 10 mg daily tablet at equivalent monthly cost, due to pill count differences in pricing algorithms at retail pharmacies. A 4-tablet monthly supply (70 mg weekly) typically costs $12 to $18 at Costco, Walmart, and Kroger pharmacies using a discount card.

What to Do If Anthem Denies Your Appeal

If both the internal appeal and the IRO external review fail, the next step depends on your plan type. Fully insured members may file a complaint with the state insurance commissioner, who has authority to audit Anthem's appeal decisions against state benchmark coverage standards. ERISA self-funded plan members have fewer state-level options but may pursue federal civil litigation under 29 U.S.C. 1132(a)(1)(B).

A more practical route for most patients is switching to a therapeutic alternative that Anthem does cover at a lower tier. Risedronate (Actonel generic) is also a first-line oral bisphosphonate covered on most Anthem formularies at Tier 1 or Tier 2. The 2019 Endocrine Society clinical practice guideline on pharmacological management of osteoporosis lists alendronate and risedronate as therapeutically equivalent first-line options for most patients [12].

If alendronate is specifically required due to prior response or physician preference, and all appeals have been exhausted, Anthem's formulary exception process allows a prescriber to request coverage of a non-formulary or non-preferred drug when a covered alternative is contraindicated or has failed. The formulary exception differs from a PA because it does not require step therapy completion; it requires only documentation that every preferred alternative is inappropriate for this specific patient.

Patients in this situation should ask their prescriber to submit a formulary exception request citing the specific covered alternatives tried or contraindicated, with supporting clinical notes. Document every phone call to Anthem with date, time, representative name, and call reference number. These records are necessary if a state insurance commissioner complaint or legal challenge becomes necessary.